AARD Q3 2023 Earnings Report — Aardvark Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

Aardvark Therapeutics, Inc. Common StockAARD

Q3 2023 Earnings

Reported September 30, 2023

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Free Cash Flow

Metric	Q3 2023	Q2 2023	Q3 2022	QoQ Change	YoY Change
Revenue	$0	—	—	—	—
Op. Income	-$2M	—	—	—	—
EPS (Diluted)	$-0.22	—	—	—	—
Free Cash Flow	-$2M	—	—	—	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$26.0K
GROSS PROFIT	-$26.0K
R&D Expenses	$964.0K
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$729.0K
Other Expenses	$0
Operating Expenses	$2M
Cost & Expenses	$2M
OPERATING INCOME	-$2M
Interest Income	$135.0K
Interest Expense	$0
Other Income/Expenses	-$390.0K
INCOME BEFORE TAX	-$2M
Income Tax Expense	$0
Net Income from Continuing Ops	-$2M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$2M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$2M
D&A	$26.0K
EBIT	-$2M
EBITDA	-$2M
EPS	-$0
EPS Diluted	-$0

Cash Flow Statement

Item	Amount
Net Income	-$2M
Depreciation & Amortization	$26.0K
Stock-Based Compensation	$72.0K
Deferred Income Tax	$0
Other Non-Cash Items	$742.0K
Change in Working Capital	-$316.0K
OPERATING CASH FLOW	-$2M
Capital Expenditure	$0
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$0
NET CASH FROM INVESTING	$0
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$0
FREE CASH FLOW	-$2M
Net Change in Cash	-$2M